RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate
summary and update regarding the Company's clinical programs at the
following investor conferences:
-
Jefferies Global Healthcare Conference in New York on Monday, June 4,
2012 at 3:00 p.m. Eastern Time
-
Wells Fargo Securities Research & Economics Healthcare Conference in
Boston on Wednesday, June 20, 2012 at 10:35 a.m. Eastern Time
Links to live audio webcasts and replays of both presentations may be
accessed on the BioCryst website at www.BioCryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases. BioCryst currently has two late-stage development
programs: peramivir,
a viral neuraminidase inhibitor for the treatment of influenza, and BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst is advancing two preclinical programs
towards IND filings: BCX5191,
a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis
C, and BCX4161,
an oral inhibitor of plasma kallikrein for hereditary angioedema.
Utilizing state-of-the-art structure-guided drug design and
crystallography, BioCryst continues to discover innovative compounds
with the goal of addressing unmet medical needs of patients and
physicians. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media